Regulatory Post Marketing Surveillance Study on Nexavar®
NCT01012011
·
clinicaltrials.gov ↗
COMPLETED
Status
2845
Enrollment
INDUSTRY
Sponsor class
Conditions
Carcinoma, Hepatocellular
Carcinoma, Renal Cell
Interventions
DRUG:
Sorafenib (Nexavar, BAY43-9006)
Sponsor
Bayer